Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: An observational study

Current Medical Research and Opinion

Volumn 21, Issue 5, 2005, Pages 723-732

  Klinger, Tatjana ^a   Ibach, Bernd ^b   Schoenknecht, Peter ^c   Kamleiter, Martin ^d   Silver, Gabrielle ^e   Schroeder, Johannes ^c   Mielke, Ruediger ^f  

^a Klinikum St Georg   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Eisai GmbH   (Germany)

^e EISAI CO LTD   (Japan)

^f UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Alzheimer's disease; Donepezil; Memantine; Nootropics; Observational study; Post marketing surveillance

Indexed keywords

AMITRIPTYLINE; DONEPEZIL; DOXEPIN; GINKGO BILOBA EXTRACT; MELPERONE; MEMANTINE; MIRTAZAPINE; NICERGOLINE; NIMODIPINE; NOOTROPIC AGENT; PIPAMPERONE; PIRACETAM; PSYCHOTROPIC AGENT; RIVASTIGMINE; TRANQUILIZER;

ADULT; AGED; AGGRESSIVENESS; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; GERMANY; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; NAUSEA; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; RESTLESSNESS; SIDE EFFECT; SLEEP DISORDER; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FEMALE; GERMANY; HUMANS; INDANS; MALE; MEMANTINE; MIDDLE AGED; NOOTROPIC AGENTS; OBSERVATION; PIPERIDINES; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME;

EID: 18844442028     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X43668     Document Type: Article

References (37)

1. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 Suppl 5):S10-5
2. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 Suppl 5):S4-9
3. Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-47
4. Blass J. Pathophysiology of Alzheimer's syndrome. Neurology 1993;43(Suppl 4):25-38
5. Battus RT, Dean RL 3rd, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-14
6. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998;158:1021-31
7. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-45
8. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-44
9. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [published erratum appears in Neurology 2001;57:1942]. Neurology 2001;57:481-8
10. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95
11. Relkin N, Reichman W, Orazem J, et al. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 2003;16:15-24
12. Boada-Rovira M, Brodaty H, Cras P, et al. Efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a global, multinational, clinical experience study. Drugs Aging 2004;21:43-53
13. Hager K, Calabrese P, Frolich L, et al. An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 2003;15:189-98
14. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-20
15. Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002;14:389-404
16. Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 2003;51:737-44
17. Gauthier S, Feldman H, Hecker J, et al. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Curr Med Res Opin 2002;18:347-54
18. Feldman H, Gauthier S, Hecker J, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: A subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2005 [in press]
19. Wimo A, Winblad B, Shah SN, et al. Impact of donepezil treatment for Alzheimer's disease on caregiver time. Curr Med Res Opin 2004;20:1221-5
20. Wlmo A, Winblad B, Engedal K, et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 2003;15:44-54
21. Feldman H, Gauthier S, Hecker J, et al. Economic evaluation of donepezil in moderate to severe Alzheimer's disease. Neurology 2004;63:644-50
22. Kilpatrick GJ, Tilbrook GS. Memantine. Merz. Curr Opin Investig Drugs 2002;3:798-806
23. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41
24. Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002;4: CD003120
25. Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev 2001;2:CD001011
26. Fioravanti M, Flicker L. Nicergoline for dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev 2001;4:CD003159
27. Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002;3:CD000147
28. Burkart M, Heun R, Maier W, et al. Dementia screening in routine clinical practice. A comparative analysis of MMSE, SIDAM and ADAS. Nervenarzt 1998;69:983-90
29. Burns A, Byrne EJ, Maurer K. Alzheimer's disease. Lancet 2002;360:163-5
30. Whitehead A, Perdomo C, Pratt R, et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomized controlled trials. Int J Geriatr Psychiatry 2004;19:624-33
31. Mack JL, Whitehouse PJ. Quality of Life in Dementia: state of the art - report of the International Working Group for Harmonization of Dementia Drug Guidelines and the Alzheimer's Society satellite meeting. Alzheimer Dis Assoc Disord 2001;15:69-71
32. Demers L, Oremus M, Perrault A, et al. Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of functional and quality of life scales. J Geriatr Psychiatry Neurol 2000;13:170-80
33. Rogers SL, Friedhoff LT. The Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303
34. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease (Cochrane Review). In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd
35. O'Leary M, Brodaty H, et al. The Australian Donepezil Study Group. Effects of donepezil on patient health-related quality of life and caregiver perception in Alzheimer's disease: preliminary findings from the Australian subset of a global clinical experience study. Neurobiol Aging 2000;21(Suppl 1):S146 (658)
36. Pratt RD, Perdomo CA, Surick IW, et al. Donepezil: tolerability and safety in Alzheimer's disease. Int J Clin Pract 2002;56:710-17
37. Johannsen P, Barcikowska M, Heun R, et al. Donepezil-treated Alzheimer's disease patients with apparent initial cognitive decline demonstrate significant benefits when therapy is continued: Results from a randomized, placebo-controlled trial. J Neurol 2003;250(Suppl 2):II/126